Cabaletta Bio Inc.

14.74-0.8900-5.69%Vol 1.76M1Y Perf 212.60%
Dec 6th, 2023 16:00 DELAYED
BID14.50 ASK15.68
Open15.74 Previous Close15.63
Pre-Market- After-Market14.89
 - -  0.15 1.02%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
-32.16 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
69.15 
Earnings Rating
Market Cap631.60M 
Earnings Date
9th Nov 2023
Alpha0.05 Standard Deviation0.42
Beta2.42 

Today's Price Range

14.6516.08

52W Range

4.4319.34

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Neutral
Performance
1 Week
-8.16%
1 Month
-8.39%
3 Months
3.95%
6 Months
25.13%
1 Year
212.60%
3 Years
-6.71%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CABA14.74-0.8900-5.69
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.39-0.375.13
Q02 2023-0.47-0.3721.28
Q01 2023-0.48-0.456.25
Q04 2022-0.47-0.52-10.64
Q03 2022-0.49-0.3920.41
Q02 2022-0.52-0.4513.46
Q01 2022-0.64-0.4529.69
Q04 2021-0.68-0.4927.94
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.39
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.76M
Shares Outstanding42.85K
Shares Float27.52M
Trades Count14.96K
Dollar Volume26.81M
Avg. Volume1.50M
Avg. Weekly Volume1.73M
Avg. Monthly Volume1.68M
Avg. Quarterly Volume1.10M

Cabaletta Bio Inc. (NASDAQ: CABA) stock closed at 14.74 per share at the end of the most recent trading day (a -5.69% change compared to the prior day closing price) with a volume of 1.76M shares and market capitalization of 631.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Cabaletta Bio Inc. CEO is Steven Nichtberger.

The one-year performance of Cabaletta Bio Inc. stock is 212.6%, while year-to-date (YTD) performance is 59.35%. CABA stock has a five-year performance of %. Its 52-week range is between 4.43 and 19.34, which gives CABA stock a 52-week price range ratio of 69.15%

Cabaletta Bio Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 2.98, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -47.75%, a ROC of -51.09% and a ROE of -50.54%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cabaletta Bio Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.39 for the next earnings report. Cabaletta Bio Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cabaletta Bio Inc. is Strong Buy (1), with a target price of $10, which is -32.16% compared to the current price. The earnings rating for Cabaletta Bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cabaletta Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cabaletta Bio Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.66, ATR14 : 1.66, CCI20 : -55.01, Chaikin Money Flow : 0.00, MACD : 0.10, Money Flow Index : 49.85, ROC : -10.38, RSI : 47.26, STOCH (14,3) : 62.87, STOCH RSI : 0.33, UO : 52.46, Williams %R : -37.13), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cabaletta Bio Inc. in the last 12-months were: Gwendolyn Binder (Sold 0 shares of value $-33 330 ), Gwendolyn Binder (Sold 33 000 shares of value $536 100 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (100.00 %)
8 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its technology uses chimeric autoantibody receptor T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies while sparing normal B cells. The firm offers preclinical development for the treatment of muscle-specific kinase myasthenia gravis, mucocutaneous PV, and Hemophilia A with factor VIII, or FVIII, alloantibodies. Its products comprise of DSG3/1-CAART, MuSK-CAART, and FVIII-CAART. The firm's initial focus is on Pemphigus Vulgaris, which is an autoimmune blistering skin disease.

CEO: Steven Nichtberger

Telephone: +1 267 759-3100

Address: 2929 Arch Street, Philadelphia 19104, PA, US

Number of employees: 31

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

 

TipRanks News for CABA

Tue, 28 Nov 2023 16:36 GMT Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies

- TipRanks. All rights reserved.

Tue, 05 Sep 2023 08:35 GMT Cabaletta Bio (CABA) Receives a Buy from Citi

- TipRanks. All rights reserved.

News

Stocktwits